R1	Has_qualifier Arg1:T1 Arg2:T2	
R2	Has_negation Arg1:T7 Arg2:T8	
R3	Has_qualifier Arg1:T5 Arg2:T7	
R4	Has_mood Arg1:T5 Arg2:T6	
R5	Has_value Arg1:T10 Arg2:T11	
R6	Has_value Arg1:T12 Arg2:T13	
R7	Subsumes Arg1:T17 Arg2:T18	
R8	Subsumes Arg1:T20 Arg2:T21	
R9	Has_value Arg1:T22 Arg2:T20	
R10	Has_value Arg1:T19 Arg2:T17	
*	OR T19 T22
R11	AND Arg1:T16 Arg2:T19	
R12	Has_value Arg1:T14 Arg2:T15	
*	OR T14 T16
R13	Has_mood Arg1:T26 Arg2:T27	
R14	Has_qualifier Arg1:T25 Arg2:T24	
R15	Has_qualifier Arg1:T25 Arg2:T28	
T1	Condition 0 4	T2DM
T2	Qualifier 19 63	American Diabetes Association (ADA) criteria
T3	Person 65 70	Adult
T4	Condition 85 89	T2DM
T5	Drug 119 130	liraglutide
T6	Mood 98 118	indicated to receive
T7	Qualifier 139 157	first-line therapy
T8	Negation 132 135	not
T9	Non-representable 159 219	in addition to diet and exercise to improve glycemic control
T10	Measurement 221 243	Hemoglobin A1c (HbA1c)
T11	Value 244 248	= 9%
T12	Person 250 253	Age
T13	Value 254 268	= 18 years old
T14	Measurement 270 291	Body mass index (BMI)
T15	Value 292 302	= 27 Kg/m2
T16	Measurement 310 329	waist circumference
T17	Value 330 338	= 102 cm
T18	Value 340 349	40 inches
T19	Person 354 357	men
T20	Value 362 367	88 cm
T21	Value 369 378	35 inches
T22	Person 383 388	women
T24	Qualifier 420 443	angiographically stable
T25	Condition 444 447	CAD
T26	Procedure 461 465	CABG
T27	Mood 452 460	requires
T28	Qualifier 405 415;437 443	Clinically stable
T29	Non-representable 504 691	as CAD does not represent a contraindication for using liraglutide. The stability of the CAD further warranties that study patients will not be exposed to higher risk by using liraglutide
